List of Excipients in Branded Drug BELRAPZO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eagle Pharmaceuticals Inc	BELRAPZO	bendamustine hydrochloride	42367-521	MONOTHIOGLYCEROL
Eagle Pharmaceuticals Inc	BELRAPZO	bendamustine hydrochloride	42367-521	POLYETHYLENE GLYCOL 400
Eagle Pharmaceuticals Inc	BELRAPZO	bendamustine hydrochloride	42367-521	PROPYLENE GLYCOL
Eagle Pharmaceuticals Inc	BELRAPZO	bendamustine hydrochloride	42367-521	SODIUM HYDROXIDE

Belrapzo Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Belrapzo is a ready-to-dilute bendamustine hydrochloride injection that uses a solvent-based liquid formulation rather than the lyophilized presentation used by earlier bendamustine products. Its commercial value is tied to preparation-time reduction, dosing convenience, and supply reliability. The strongest excipient opportunities are formulation replication, preservative-free ready-to-use presentations, lower-toxicity solvent systems, container-closure optimization, and differentiated premixed products.

What is Belrapzo and how is it formulated?

Belrapzo is bendamustine hydrochloride injection, approved for intravenous treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.[1]

The marketed presentation is a 25 mg/mL solution in a single-dose vial. The standard vial contains 100 mg of bendamustine hydrochloride in 4 mL. The formulation is diluted before administration and is intended to reduce the preparation burden associated with reconstituting lyophilized bendamustine products.[1]

Belrapzo excipients

The Belrapzo label identifies the following inactive ingredients:

Excipient	Likely formulation role
N,N-dimethylacetamide	Primary cosolvent for bendamustine hydrochloride
Propylene glycol	Cosolvent and solubility-supporting vehicle
Polyethylene glycol 400	Cosolvent, viscosity modifier, and stabilizing vehicle

The formulation does not depend on a conventional aqueous buffer as its principal solubility mechanism. This is important because bendamustine has limited aqueous solubility and can undergo degradation in solution. The solvent system permits a concentrated liquid presentation, but it creates toxicological, extractables, packaging, and administration constraints.

What excipient strategy does Belrapzo use?

Belrapzo's formulation strategy is based on maintaining bendamustine in a concentrated liquid state until dilution at the point of care. The strategy has four commercial objectives:

1. Avoid lyophilization and reconstitution.
2. Support a 25 mg/mL concentration.
3. Permit withdrawal from a single-dose vial and dilution into an infusion solution.
4. Preserve chemical stability over the labeled shelf life.

The principal technical tradeoff is between solubility and solvent burden. N,N-dimethylacetamide, propylene glycol, and polyethylene glycol 400 support drug loading but increase the need for toxicological justification and compatibility testing.

What excipient risks affect Belrapzo?

The principal risks are:

• Solvent tolerability: N,N-dimethylacetamide has a more significant regulatory and toxicological profile than common aqueous excipients.
• Dilution compatibility: The concentrated product must remain physically and chemically stable after dilution into approved infusion media.
• Precipitation: Changes in temperature, dilution ratio, infusion concentration, or diluent composition can affect precipitation risk.
• Container interaction: Polyethylene glycol 400 and propylene glycol can interact with elastomeric closures, plastic components, or syringe materials.
• Extractables and leachables: The organic solvent system increases the importance of vial, stopper, and administration-set studies.
• Infusion-site tolerability: The formulation and final diluted concentration must be evaluated for irritation and handling requirements.
• Occupational handling: Bendamustine is a cytotoxic antineoplastic agent, so closed-system transfer and hazardous-drug controls remain relevant regardless of excipient choice.[2]

What formulations are protected by Belrapzo's product strategy?

The commercial differentiation is primarily associated with the liquid, ready-to-dilute formulation and its manufacturing process. A competing product could seek protection or differentiation through several formulation categories:

Concentrated liquid injection

A direct or improved liquid formulation would compete most closely with Belrapzo. Potential claim scope could cover:

• Bendamustine concentration range.
• Ratios of N,N-dimethylacetamide, propylene glycol, and polyethylene glycol 400.
• pH or water content.
• Dilution stability.
• Storage temperature.
• Container-closure configuration.
• Degradation-product limits.
• Specific manufacturing order and mixing conditions.

A formulation that uses the same excipients may face patent and regulatory scrutiny if it relies on the same concentration, ratio, process, or stability profile. A product using a materially different solvent system may avoid some intellectual-property barriers but face a more demanding CMC program.

Lyophilized powder

Lyophilized bendamustine remains a commercially relevant alternative. It may reduce solvent exposure but imposes reconstitution steps, longer pharmacy preparation, and increased handling complexity. A lyophilized product could use mannitol, sucrose, trehalose, or other bulking and stabilizing agents, subject to compatibility with bendamustine and the required reconstitution profile.

Premixed infusion

A premixed bag would offer the greatest workflow advantage but also presents the most demanding stability and packaging requirements. Commercial development would need to address:

• Long-term stability after compounding.
• Light sensitivity.
• Bag and tubing compatibility.
• Adsorption to administration components.
• Precipitation during refrigerated storage.
• Microbial control.
• Transport under temperature excursions.
• Hazardous-drug packaging and labeling.

Premixed products could command a price premium if they reduce pharmacy labor and preparation errors. The business case is strongest in high-volume oncology centers and integrated delivery networks.

How can a competitor design around Belrapzo's excipients?

A design-around program should avoid treating excipient substitution as a simple ingredient swap. The product must preserve concentration, stability, dilution behavior, and clinical usability.

Option 1: Reduce or eliminate N,N-dimethylacetamide

This is the clearest differentiation route from Belrapzo's disclosed solvent system. Candidate approaches could include:

• Higher polyethylene glycol 400 content.
• Alternative glycols or polyols.
• Ethanol-containing systems, subject to tolerability and flammability considerations.
• Complexation or cosolvent combinations.
• pH-controlled aqueous systems.
• Micellar, lipid, or polymeric solubilization.

The principal risk is that a lower-toxicity solvent system may require a lower drug concentration, which could eliminate the operational advantage of Belrapzo.

Option 2: Develop an aqueous or buffered formulation

An aqueous formulation could improve excipient familiarity and reduce solvent-related objections. The technical challenge is preserving bendamustine stability at clinically useful concentrations. A buffered system would require extensive evaluation of:

• pH-dependent degradation.
• Hydrolysis.
• Formation of bendamustine-related impurities.
• Compatibility with common infusion diluents.
• Container-closure adsorption.
• Stability after dilution.

This approach may create a stronger formulation patent position if it achieves a concentration and shelf life not disclosed by existing products.

Option 3: Use a solid-state presentation

A new lyophilized or spray-dried product could target hospitals that prioritize solvent reduction over preparation speed. Excipients such as mannitol, sucrose, trehalose, or amino acids could support cake structure and reconstitution. The product would need to demonstrate rapid reconstitution, low particulate burden, and a clinically acceptable reconstitution volume.

Option 4: Improve the administration system

Commercial differentiation does not have to come from a new active formulation. Opportunities include:

• Ready-to-use syringes.
• Dual-chamber vials.
• Closed-system transfer-compatible packaging.
• Premixed infusion bags.
• Smaller-dose vials to reduce overfill and waste.
• Barcode-enabled unit-dose packaging.
• Low-volume presentations for weight-based dosing.

These products could rely on device, packaging, or process intellectual property rather than a wholly new excipient composition.

What FDA regulatory pathway applies to a new Belrapzo competitor?

A bendamustine product may be eligible for an abbreviated new drug application if the applicant can establish pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. A materially different formulation, route, concentration, dosage form, or clinical use may require a 505(b)(2) application.[3]

The regulatory assessment depends heavily on the formulation:

Product concept	Likely regulatory issue
Same strength, same dosage form, equivalent inactive ingredients	Potential ANDA pathway
Same active ingredient with materially different excipients	ANDA feasibility depends on equivalence and inactive-ingredient justification
New concentration	Pharmaceutical-equivalence and safety assessment
Premixed infusion bag	New stability, packaging, and administration evidence
New route or delivery technology	Likely 505(b)(2) or full development
Lyophilized product with different excipients	Reconstitution and equivalence requirements
New indication	Method-of-use exclusivity and clinical-support requirements

For an injectable cytotoxic product, FDA scrutiny will focus on sterility assurance, particulate matter, visible and subvisible particles, extractables and leachables, endotoxin control, container closure, and manufacturing-process validation.[4]

What is the Orange Book and patent status of Belrapzo?

Belrapzo was approved under NDA 208579 in 2018.[1] The product is a small-molecule injectable, so biosimilar provisions do not apply. Competitive entry would generally involve an ANDA or, for a materially differentiated formulation, a 505(b)(2) application.

The principal intellectual-property categories are:

• Bendamustine compound patents, most of which predate Belrapzo.
• Liquid formulation patents.
• Concentration and solvent-ratio claims.
• Dilution and stability claims.
• Manufacturing-process patents.
• Container-closure and administration-system claims.
• Method-of-use patents covering specific treatment settings.

The FDA Orange Book remains the controlling source for current listed patents, use codes, expiration dates, and pediatric exclusivity.[5] A competitor must conduct a current Orange Book review and a broader patent search because formulation and process rights may not all appear in the Orange Book.

A Paragraph IV strategy would be most relevant if a listed patent remains in force and blocks an ANDA route. The applicant would need to certify that the patent is invalid, unenforceable, or will not be infringed. A notice letter could trigger litigation under the Hatch-Waxman framework and potentially a 30-month stay, subject to the statutory requirements.[6]

When does Belrapzo lose exclusivity?

Belrapzo's five-year new chemical entity exclusivity was not the relevant commercial protection because bendamustine was previously approved in the United States. The product's 2018 approval could support three-year exclusivity for certain new clinical investigations or changes, but that period would not ordinarily block all generic bendamustine products.

The practical entry question is therefore patent-driven rather than exclusivity-driven. An applicant must evaluate:

• Current Orange Book-listed patents.
• Patent expiration dates.
• Pediatric exclusivity extensions.
• Litigation or settlement agreements.
• Non-Orange-Book formulation and process patents.
• Regulatory requirements for injectable equivalence.

No biosimilar exclusivity framework applies because bendamustine is a synthetic small molecule.

What commercial opportunities exist for excipient suppliers?

The highest-value opportunities are not limited to selling commodity excipients. Suppliers can create differentiated value through qualified, oncology-focused formulation platforms.

Excipient and formulation opportunities

• Low-peroxide polyethylene glycol 400 grades.
• High-purity propylene glycol with controlled trace impurities.
• Alternative cosolvents with lower toxicological burden.
• Ready-to-use solvent blends.
• Excipient packages qualified for cytotoxic injectables.
• Low-extractables elastomers and polymer containers.
• Stability-indicating analytical methods.
• Dilution-compatible infusion systems.
• Premixed bag technologies.

Suppliers that can provide regulatory documentation, compendial compliance, extractables data, and reliable global supply will have an advantage over suppliers selling only the chemical ingredient.

Manufacturing and CDMO opportunities

A CDMO can target:

• Liquid bendamustine formulation development.
• Aseptic filling into single-dose vials.
• Premixed infusion manufacturing.
• Lyophilization and reconstitution optimization.
• Small-batch clinical supply.
• Analytical method development.
• Cytotoxic manufacturing suites.
• Packaging and device compatibility testing.

The manufacturing barrier is meaningful. Cytotoxic sterile filling requires specialized facilities, validated containment, and robust occupational controls. This limits the number of credible suppliers and supports outsourcing opportunities.

How strong is the commercial opportunity?

The opportunity is strongest where a product reduces pharmacy labor, preparation time, vial waste, or hazardous-drug exposure. The most attractive segments are:

1. Hospitals with high bendamustine utilization.
2. Oncology networks seeking standardized preparation.
3. Specialty pharmacies and ambulatory infusion centers.
4. Health systems with closed-system transfer requirements.
5. Markets where cold-chain and sterile compounding capacity are constrained.

A direct liquid generic would likely face price pressure. A premixed or workflow-optimized formulation could preserve higher margins if it demonstrates measurable reductions in preparation time and waste.

What competitive risks exist for a new Belrapzo formulation?

The key risks are:

• ANDA competition using an equivalent formulation.
• Price erosion after generic entry.
• Patent litigation over solvent composition or manufacturing.
• Failure to demonstrate injectable equivalence.
• Precipitation after dilution.
• Limited shelf life.
• Supply-chain volatility for specialized solvents.
• Hospital reluctance to adopt a new handling protocol.
• Manufacturing costs that exceed the price premium.
• Toxicological concerns related to the solvent system.

A successful development program should establish the target product profile before selecting excipients. The central commercial decision is whether to pursue a lower-cost direct generic, a lower-solvent formulation, or a higher-value ready-to-use product.

Key Takeaways

• Belrapzo is a 25 mg/mL bendamustine hydrochloride liquid injection in a 100 mg/4 mL single-dose vial.
• Its disclosed excipient system uses N,N-dimethylacetamide, propylene glycol, and polyethylene glycol 400.
• The primary product advantage is avoidance of lyophilized-product reconstitution.
• The strongest formulation design-around is a lower-solvent or aqueous system that preserves concentration and stability.
• Premixed bags and ready-to-use administration formats offer the clearest commercial differentiation.
• Belrapzo is a small-molecule product, so biosimilar risk does not apply.
• Generic entry depends mainly on current patent listings, formulation equivalence, and injectable-product CMC requirements.
• Excipient suppliers can compete through qualified solvent systems, regulatory data packages, packaging compatibility, and oncology-focused CDMO services.

FAQs

Can polyethylene glycol 400 replace N,N-dimethylacetamide in Belrapzo?

Not automatically. Increasing polyethylene glycol 400 may affect viscosity, solubility, dilution behavior, infusion tolerability, and stability. A replacement formulation would require a separate CMC and toxicological justification.

Is Belrapzo a preservative-containing product?

Belrapzo is supplied as a single-dose vial. The commercial presentation is not designed as a multidose preserved product, and preservative addition would require compatibility, safety, and regulatory evaluation.

Could a premixed bendamustine infusion receive a price premium?

Yes, if it reduces pharmacy compounding labor, hazardous-drug handling, vial waste, and preparation errors. The premium would depend on demonstrated stability and adoption by hospital purchasing organizations.

Does a bendamustine generic need to use the same excipients as Belrapzo?

No. The applicant must satisfy applicable pharmaceutical-equivalence, bioequivalence, safety, quality, and injectable-product requirements. A different excipient system may change the regulatory pathway or require additional justification.

Which excipient property is most important for a Belrapzo design-around?

Solubility support at the target concentration is the first constraint. The formulation must then meet stability, dilution compatibility, tolerability, packaging, sterility, and manufacturing requirements.

References

1. U.S. Food and Drug Administration. (2018). Belrapzo (bendamustine hydrochloride) injection prescribing information. NDA 208579.

2. U.S. National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings.

3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).

4. U.S. Food and Drug Administration. (2021). Sterile drug products produced by aseptic processing: Current good manufacturing practice.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.

6. U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications for new drugs.